Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Core Insights - Atossa Therapeutics, Inc. has requested a Type C meeting with the U.S. FDA to discuss a regulatory strategy for accelerating the development of low-dose (Z)-endoxifen aimed at breast cancer risk reduction [1] Company Developments - The meeting with the FDA is a significant step for Atossa as it seeks to expedite the development process for its breast cancer treatment [1] - The focus on low-dose (Z)-endoxifen indicates the company's commitment to addressing breast cancer risk through innovative therapeutic approaches [1] Industry Context - The request for a Type C meeting reflects the ongoing efforts within the pharmaceutical industry to engage with regulatory bodies to streamline drug development processes [1] - Accelerating the development of treatments for breast cancer aligns with broader industry trends focused on improving patient outcomes and reducing risks associated with cancer therapies [1]